<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34996385</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2377</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC neurology</Title>
          <ISOAbbreviation>BMC Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson's disease patients.</ArticleTitle>
        <Pagination>
          <StartPage>13</StartPage>
          <MedlinePgn>13</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">13</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-021-02544-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Parkinson's disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson's symptoms.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson's symptoms and the potential effects of medications on the serum SCFAs was analyzed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson's Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson's symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Zhengli</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pu</LastName>
            <ForeName>Yaling</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Medical College, Shaoxing University of Arts and Sciences, Shaoxing, 312099, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Shiyong</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical laboratory Department, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tingling</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yajing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiaoping</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shanshan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Minya</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical laboratory Department, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yangyang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Health Management Center, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Saarland University, 66421, Homburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Shaofa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China. kesf@enzemed.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Suzhi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang, China. liusz@enzemed.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Medical College, Shaoxing University of Arts and Sciences, Shaoxing, 312099, Zhejiang, China. liusz@enzemed.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Neurol</MedlineTA>
        <NlmUniqueID>100968555</NlmUniqueID>
        <ISSNLinking>1471-2377</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005232" MajorTopicYN="N">Fatty Acids, Volatile</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cognitive Impairment</Keyword>
        <Keyword MajorTopicYN="N">Depression</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s Disease</Keyword>
        <Keyword MajorTopicYN="N">Propionic Acid</Keyword>
        <Keyword MajorTopicYN="N">Short-Chain Fatty Acids</Keyword>
        <Keyword MajorTopicYN="N">tizanidine</Keyword>
        <Keyword MajorTopicYN="N">trihexyphenidyl</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34996385</ArticleId>
        <ArticleId IdType="pmc">PMC8740341</ArticleId>
        <ArticleId IdType="doi">10.1186/s12883-021-02544-7</ArticleId>
        <ArticleId IdType="pii">10.1186/s12883-021-02544-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–1345. doi: 10.1016/j.cell.2016.05.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.05.041</ArticleId>
            <ArticleId IdType="pubmed">27259147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. doi: 10.1080/19490976.2015.1134082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19490976.2015.1134082</ArticleId>
            <ArticleId IdType="pmc">PMC4939913</ArticleId>
            <ArticleId IdType="pubmed">26963409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, et al.  The role of the gut microbiota in the pathogenesis of Parkinson's disease. Front Neurol. 2019;10:1155. doi: 10.3389/fneur.2019.01155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.01155</ArticleId>
            <ArticleId IdType="pmc">PMC6851172</ArticleId>
            <ArticleId IdType="pubmed">31781020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al.  Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30(10):1351–1360. doi: 10.1002/mds.26307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26307</ArticleId>
            <ArticleId IdType="pubmed">26179554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al.  Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun. 2018;70:194–202. doi: 10.1016/j.bbi.2018.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2018.02.016</ArticleId>
            <ArticleId IdType="pubmed">29501802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldini F, Hertel J, Sandt E, Thinnes CC, Neuberger-Castillo L, Pavelka L, et al.  Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol. 2020;18:1:62. doi: 10.1186/s12915-020-00775-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12915-020-00775-7</ArticleId>
            <ArticleId IdType="pmc">PMC7285525</ArticleId>
            <ArticleId IdType="pubmed">32517799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheperjans F, Aho V, Pereira P, Koskinen K, Paulin L, Pekkonen E, et al.  Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30(3):350–358. doi: 10.1002/mds.26069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26069</ArticleId>
            <ArticleId IdType="pubmed">25476529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, et al.  Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease. Front Neurol. 2020;11:137. doi: 10.3389/fneur.2020.00137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00137</ArticleId>
            <ArticleId IdType="pmc">PMC7052381</ArticleId>
            <ArticleId IdType="pubmed">32161568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, et al.  Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72. doi: 10.1016/j.parkreldis.2016.08.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2016.08.019</ArticleId>
            <ArticleId IdType="pubmed">27591074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, et al.  Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease. Mov Disord. 2020;35(7):1208–1217. doi: 10.1002/mds.28052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.28052</ArticleId>
            <ArticleId IdType="pubmed">32357258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review. J Funct Foods. 2016;25:511–522. doi: 10.1016/j.jff.2016.06.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jff.2016.06.032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al.  Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's Disease. Cell. 2016;167(6):1469–80.e12. doi: 10.1016/j.cell.2016.11.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId>
            <ArticleId IdType="pmc">PMC5718049</ArticleId>
            <ArticleId IdType="pubmed">27912057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulak A. A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease. Mov Disord. 2018;33(3):398–401. doi: 10.1002/mds.27304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.27304</ArticleId>
            <ArticleId IdType="pubmed">29436731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, et al.  Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. Microbiome. 2021;9(1):34. doi: 10.1186/s40168-020-00988-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-020-00988-6</ArticleId>
            <ArticleId IdType="pmc">PMC7849090</ArticleId>
            <ArticleId IdType="pubmed">33517890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Group of Parkinson's Disease and Movement Disorders NBoCMAPCoPsDaMDoNBoCPA  Diagnostic criteria of Parkinson's disease in China (2016 edition) Chin J Neurol. 2016;49(4):268–271. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.1006-7876.2016.04.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–2653. doi: 10.1002/mds.23429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.23429</ArticleId>
            <ArticleId IdType="pubmed">21069833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair AT, Ramachandran V, Joghee NM, Antony S, Ramalingam G. Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson&amp;rsquo;s Disease: A Critical Review. J Neurogastroenterol Motil. 2018;24(1):30–42. doi: 10.5056/jnm17105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5056/jnm17105</ArticleId>
            <ArticleId IdType="pmc">PMC5753901</ArticleId>
            <ArticleId IdType="pubmed">29291606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapelet G, Leclair-Visonneau L, Clairembault T, Neunlist M, Derkinderen P. Can the gut be the missing piece in uncovering PD pathogenesis? Parkinsonism Relat Disord. 2019;59:26–31. doi: 10.1016/j.parkreldis.2018.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2018.11.014</ArticleId>
            <ArticleId IdType="pubmed">30448099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yano Jessica M, Yu K, Donaldson Gregory P, Shastri Gauri G, Ann P, Ma L, et al.  Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell. 2015;161(2):264–276. doi: 10.1016/j.cell.2015.02.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId>
            <ArticleId IdType="pmc">PMC4393509</ArticleId>
            <ArticleId IdType="pubmed">25860609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133–148. doi: 10.1016/j.jcmgh.2018.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2018.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC6047317</ArticleId>
            <ArticleId IdType="pubmed">30023410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Long W, Zhang C, Liu S, Zhao L, Hamaker BR. Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota. Sci Rep. 2017;7(1):2594. doi: 10.1038/s41598-017-02995-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-02995-4</ArticleId>
            <ArticleId IdType="pmc">PMC5453967</ArticleId>
            <ArticleId IdType="pubmed">28572676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60(11):1761–1766. doi: 10.1212/01.Wnl.0000068021.13945.7f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.Wnl.0000068021.13945.7f</ArticleId>
            <ArticleId IdType="pubmed">12796527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palavra NC, Lubomski M, Flood VM, Davis RL, Sue CM. Increased Added Sugar Consumption Is Common in Parkinson's Disease. Frontiers. Nutrition. 2021;8:207. doi: 10.3389/fnut.2021.628845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnut.2021.628845</ArticleId>
            <ArticleId IdType="pmc">PMC8138322</ArticleId>
            <ArticleId IdType="pubmed">34026805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baert F, Matthys C, Mellaerts R, Lemaître D, Vlaemynck G, Foulon V. Dietary Intake of Parkinson's Disease Patients. Front Nutr. 2020;7:105. doi: 10.3389/fnut.2020.00105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnut.2020.00105</ArticleId>
            <ArticleId IdType="pmc">PMC7385303</ArticleId>
            <ArticleId IdType="pubmed">32793623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin C, Lim Y, Lim H, Ahn TB. Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease. Mov Disord. 2020;35(6):1021–1027. doi: 10.1002/mds.28016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.28016</ArticleId>
            <ArticleId IdType="pubmed">32154946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostendorf F, Metzdorf J, Gold R, Haghikia A, Tönges L. Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease. Molecules. 2020;25(11). 10.3390/molecules25112502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7321113</ArticleId>
            <ArticleId IdType="pubmed">32481507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoyles L, Snelling T, Umlai UK, Nicholson JK, Carding SR, Glen RC, et al.  Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier. Microbiome. 2018;6(1):55. doi: 10.1186/s40168-018-0439-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-018-0439-y</ArticleId>
            <ArticleId IdType="pmc">PMC5863458</ArticleId>
            <ArticleId IdType="pubmed">29562936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan J, Pavlovic D, Dalkie N, Waldvogel HJ, O'Carroll SJ, Green CR, et al.  Vascular degeneration in Parkinson's disease. Brain Pathol. 2013;23(2):154–164. doi: 10.1111/j.1750-3639.2012.00628.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1750-3639.2012.00628.x</ArticleId>
            <ArticleId IdType="pmc">PMC8029297</ArticleId>
            <ArticleId IdType="pubmed">22897695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pena L, Burton BK. Survey of health status and complications among propionic acidemia patients. Am J Med Genet A. 2012;158a(7):1641–1646. doi: 10.1002/ajmg.a.35387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.a.35387</ArticleId>
            <ArticleId IdType="pubmed">22678880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettenuzzo LF, Schuck PF, Fontella F, Wannmacher CM, Wyse AT, Dutra-Filho CS, et al.  Ascorbic acid prevents cognitive deficits caused by chronic administration of propionic acid to rats in the water maze. Pharmacol Biochem Behav. 2002;73(3):623–629. doi: 10.1016/s0091-3057(02)00856-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0091-3057(02)00856-0</ArticleId>
            <ArticleId IdType="pubmed">12151037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Tian T, Mao Q, Zou T, Zhou CJ, Xie J, et al.  Associations between disordered gut microbiota and changes of neurotransmitters and short-chain fatty acids in depressed mice. Transl Psychiatry. 2020;10(1):350. doi: 10.1038/s41398-020-01038-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-01038-3</ArticleId>
            <ArticleId IdType="pmc">PMC7567879</ArticleId>
            <ArticleId IdType="pubmed">33067412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobzhanidze G, Lordkipanidze T, Zhvania M, Japaridze N, MacFabe DF, Pochkidze N, et al.  Effect of propionic acid on the morphology of the amygdala in adolescent male rats and their behavior. Micron. 2019;125:102732. doi: 10.1016/j.micron.2019.102732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micron.2019.102732</ArticleId>
            <ArticleId IdType="pubmed">31437571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, et al.  The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China. Parkinsonism Relat Disord. 2014;20(2):149–152. doi: 10.1016/j.parkreldis.2013.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2013.10.005</ArticleId>
            <ArticleId IdType="pubmed">24161377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739–749. doi: 10.1002/mds.26942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26942</ArticleId>
            <ArticleId IdType="pmc">PMC5469442</ArticleId>
            <ArticleId IdType="pubmed">28195358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jameson KG, Olson CA, Kazmi SA, Hsiao EY. Toward Understanding Microbiome-Neuronal Signaling. Mol Cell. 2020;78(4):577–583. doi: 10.1016/j.molcel.2020.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.03.006</ArticleId>
            <ArticleId IdType="pubmed">32275853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Q, Wang H, Tian Y, Xu F, Chen X, Wang K. Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson's disease patients. PLoS One. 2013;8(9):e75743. doi: 10.1371/journal.pone.0075743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0075743</ArticleId>
            <ArticleId IdType="pmc">PMC3784418</ArticleId>
            <ArticleId IdType="pubmed">24086623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, et al.  The serum lipid profile of Parkinson's disease patients: a study from China. Int J Neurosci. 2015;125(11):838–844. doi: 10.3109/00207454.2014.979288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00207454.2014.979288</ArticleId>
            <ArticleId IdType="pubmed">25340257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu X, Wang Y, He X, Li H, Liu H, Zhang X. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease. Lipids Health Dis. 2020;19:1:97. doi: 10.1186/s12944-020-01284-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12944-020-01284-w</ArticleId>
            <ArticleId IdType="pmc">PMC7236933</ArticleId>
            <ArticleId IdType="pubmed">32430016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saedi S, Hemmati-Dinarvand M, Barmaki H, Mokhtari Z, Musavi H, Valilo M, et al.  Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran. Caspian J Intern Med. 2021;12(2):155–161. doi: 10.22088/cjim.12.2.155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.22088/cjim.12.2.155</ArticleId>
            <ArticleId IdType="pmc">PMC8111816</ArticleId>
            <ArticleId IdType="pubmed">34012532</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
